Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by Voya Investment Management LLC

Voya Investment Management LLC lowered its position in Keros Therapeutics, Inc. (NASDAQ:KROS) by 83.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,488 shares of the company’s stock after selling 145,806 shares during the quarter. Voya Investment Management LLC’s holdings in Keros Therapeutics were worth $467,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in KROS. AlphaQuest LLC lifted its stake in shares of Keros Therapeutics by 469.0% in the fourth quarter. AlphaQuest LLC now owns 3,596 shares of the company’s stock worth $57,000 after acquiring an additional 2,964 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in shares of Keros Therapeutics in the 4th quarter valued at approximately $90,000. Exchange Traded Concepts LLC purchased a new position in shares of Keros Therapeutics during the 4th quarter valued at approximately $99,000. CANADA LIFE ASSURANCE Co grew its position in shares of Keros Therapeutics by 207.8% during the fourth quarter. CANADA LIFE ASSURANCE Co now owns 7,371 shares of the company’s stock worth $116,000 after buying an additional 4,976 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its stake in shares of Keros Therapeutics by 19.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,589 shares of the company’s stock worth $136,000 after buying an additional 1,372 shares during the last quarter. 71.56% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Keros Therapeutics

In related news, major shareholder Adar1 Capital Management, Llc bought 934,258 shares of the stock in a transaction on Wednesday, April 9th. The shares were purchased at an average price of $10.13 per share, with a total value of $9,464,033.54. Following the purchase, the insider now owns 4,392,737 shares in the company, valued at approximately $44,498,425.81. This represents a 27.01 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. 20.60% of the stock is owned by insiders.

Keros Therapeutics Stock Performance

Keros Therapeutics stock opened at $13.65 on Friday. Keros Therapeutics, Inc. has a one year low of $9.12 and a one year high of $72.37. The company has a 50-day simple moving average of $12.20 and a 200-day simple moving average of $24.71. The firm has a market capitalization of $554.39 million, a P/E ratio of -2.62 and a beta of 1.32.

Keros Therapeutics (NASDAQ:KROS) last posted its earnings results on Tuesday, May 6th. The company reported $3.62 EPS for the quarter, topping the consensus estimate of ($0.01) by $3.63. The firm had revenue of $211.25 million during the quarter, compared to analysts’ expectations of $84.62 million. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. During the same quarter in the prior year, the firm earned ($1.21) EPS. As a group, sell-side analysts forecast that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current year.

Analyst Ratings Changes

KROS has been the subject of several recent analyst reports. HC Wainwright decreased their price objective on shares of Keros Therapeutics from $40.00 to $25.00 and set a “buy” rating for the company in a report on Thursday. Oppenheimer lowered their price objective on Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating for the company in a report on Thursday, January 16th. Piper Sandler reduced their target price on Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating on the stock in a report on Friday, January 17th. Cantor Fitzgerald downgraded Keros Therapeutics from an “overweight” rating to a “neutral” rating in a report on Tuesday, January 21st. Finally, Scotiabank reduced their price objective on Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating on the stock in a research note on Thursday, January 16th. Six analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $38.67.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.